Avalo Therapeutics, Inc. · NASDAQ:AVTX

Sullivan Christopher Ryan sold 16,915 Avalo Therapeutics, Inc. shares (Form 4)

Traded Apr 29 to Apr 30, 2026 · Filed May 1, 2026

From Apr 29 to Apr 30, 2026, Sullivan Christopher Ryan (Chief Financial Officer) sold 16,915 Avalo Therapeutics, Inc. shares at an average US$13.16 for US$223K under a trading plan, leaving 423 shares. Filed May 1, 2026 (Form 4).

Sold
16,915 shares
Price
US$13.16 average (US$13.09 to US$13.23)
Value
US$223K
Holding after
423 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 29, 2026Common StockSale8,458US$13.098,880Direct
Apr 30, 2026Common StockSale8,457US$13.23423Direct

Source

View original at SEC

Related